On January 16th, Shenzhen Ruixin Intelligent Medical Technology Co., Ltd. completed tens of millions of A-round financing. This round of financing is exclusively invested by Jingwei China. The financing will be used to further deepen and expand Ruixin Intelligent Medical in cardiovascular and cerebrovascular diseases. Development and marketing of artificial intelligence technology and bio-simulation technology in the field. Earlier, Angel Wheel was invested by Guokejiahe.
Ruixin Smart Medical was established in December 2017 and is headquartered in Shenzhen. At present, the products developed by the company are widely used in the detection of cardiovascular and cerebrovascular diseases. Ruixin Smart Medical is researching and developing intelligent medical platforms based on artificial intelligence, simulation and cloud computing to deeply explore the information in medical data to more accurately assess the condition and guide treatment.
At present, medical imaging AI technology focuses on the identification and judgment of pathological morphology, but it is impossible to speculate on the functional indicators of diseased organs. In the field of cardiovascular and cerebrovascular, the information that AI technology can provide is limited to information that clinical experts can obtain from images, such as the degree of narrowing of blood vessels extracted from coronary CT images, the properties of plaques, and so on. However, these morphological information is not sufficient to assess the blood supply function of diseased blood vessels that are highly needed by clinical experts. Currently, such functional indicators can only be obtained through very complicated and costly interventional procedures.
With the rapid development of AI medical image processing technology, is it possible to combine the other top technologies to obtain the functional indicators of blood vessels accurately and non-invasively? The use of computational simulation technology to accurately assess blood flow functional indicators is a unique technological advantage.
Based on more than a decade of research in the fields of medical imaging and bio-simulation, the company has developed a whole set of algorithms and software for artificial intelligence and fluid simulation. On this basis, the first product launched by Ruixin is the diagnostic software for evaluating cardiovascular blood supply function. Only the patient's CT image of the heart is needed to accurately calculate the blood supply function of the blood vessel and generate a diagnostic report.
Based on this diagnostic report, the doctor can decide how to use the medicine, whether to place the stent, and where to place the stent. Around this product, Ruixin also carried out a series of research and verification of cardiovascular diseases.
The three founders of Ruixin, Zheng Lingyi, Lan Hongzhi and Ma Jun are experts who have obtained doctoral degrees in famous American universities and have worked in related fields for many years. During the venture, all three took the family back to Shenzhen. Speaking of this "great migration", Zheng Lingqi said: "Our three families are in the United States for more than ten years. It is a very important decision to return home. It is very grateful to the other half for their support. We know that entrepreneurship is very Difficult things, no courage to break the boat can not be done, so we did not choose the strategy of "two places to run" adopted by many people, but completely returned to the country to invest in the cause. The United States has been leading the technology for a long time in the past, but we We firmly believe that the future of technological innovation is in China, and we are very honored to be involved."
The team's CEO, Zheng Lingqi, holds a bachelor's degree from Beihang University and Johns Hopkins University and has been engaged in biological simulation research for more than 10 years. Years of research and development experience has enabled Zheng Lingyi to develop a plan to use non-invasive screening for cardiovascular disease with simulation technology.
At present, Ruixin Smart Medical has a research and development team in Silicon Valley, USA, and has reached cooperation intentions with major research units such as Johns Hopkins University, Stanford University, Beijing Fuwai Hospital, and Shanghai Zhongshan Hospital.
Half Shell Mussel,Frozen Cooked Half Shell Mussel,Seafood Frozen Half Shell Mussel,Frozen Half Shell Mussel
Shengsi Xiangyuan Aquatic Products Co.,Ltd., , https://www.xiangyuan-aquatic.com